BR112014032567A2 - purificação de iduronato-2-sulfatase - Google Patents

purificação de iduronato-2-sulfatase

Info

Publication number
BR112014032567A2
BR112014032567A2 BR112014032567A BR112014032567A BR112014032567A2 BR 112014032567 A2 BR112014032567 A2 BR 112014032567A2 BR 112014032567 A BR112014032567 A BR 112014032567A BR 112014032567 A BR112014032567 A BR 112014032567A BR 112014032567 A2 BR112014032567 A2 BR 112014032567A2
Authority
BR
Brazil
Prior art keywords
protein
present
iduronate
sulfatase
purification
Prior art date
Application number
BR112014032567A
Other languages
English (en)
Other versions
BR112014032567B1 (pt
Inventor
Nichols Dave
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014032567(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of BR112014032567A2 publication Critical patent/BR112014032567A2/pt
Publication of BR112014032567B1 publication Critical patent/BR112014032567B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

abstract the present invention provides, among other things, improved methods for purifying i2s protein produced recombinantly for enzyme replacement therapy. the present invention is, in part, based on the surprising discovery that recombinant i2s protein can be purified from unprocessed biological materials, such as, i2s-containing cell culture medium, using a process involving as few as four chromatography columns. ________________ tradução do resumo resumo "purificação de iduronato-2-sulfatase". a presente invenção fornece, entre outras coisas, métodos aperfeiçoados para purificar proteína i2s produzida recombinantemen-te para terapia de reposição de enzima. a presente invenção é, em parte, baseada na descoberta surpreendente que a proteína i2s recombinante pode ser purificada de materiais biológicos não processa-dos, tal como, meio de cultura de célula contendo i2s usando um processo envolvendo tão pouco quanto quatro colunas de cromatografia.
BR112014032567-7A 2012-06-29 2013-06-28 Composições compreendendo iduronato-2-sulfatase (i2s) recombinante purificada e seu uso BR112014032567B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
US61/666,733 2012-06-29
PCT/US2013/048561 WO2014005014A2 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Publications (2)

Publication Number Publication Date
BR112014032567A2 true BR112014032567A2 (pt) 2017-08-01
BR112014032567B1 BR112014032567B1 (pt) 2022-09-13

Family

ID=49778401

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032567-7A BR112014032567B1 (pt) 2012-06-29 2013-06-28 Composições compreendendo iduronato-2-sulfatase (i2s) recombinante purificada e seu uso

Country Status (38)

Country Link
US (6) US9051556B2 (pt)
EP (2) EP2867245B1 (pt)
JP (4) JP6171007B2 (pt)
KR (5) KR101380740B1 (pt)
CN (3) CN107596358A (pt)
AR (1) AR091647A1 (pt)
AU (3) AU2013282395C1 (pt)
BR (1) BR112014032567B1 (pt)
CA (2) CA2877517C (pt)
CL (1) CL2014003567A1 (pt)
CO (1) CO7240396A2 (pt)
CR (1) CR20140588A (pt)
CY (1) CY1121519T1 (pt)
DK (1) DK2867245T3 (pt)
DO (1) DOP2014000294A (pt)
EA (2) EA202090044A1 (pt)
ES (1) ES2689468T3 (pt)
GT (1) GT201400303A (pt)
HK (4) HK1209431A1 (pt)
HR (1) HRP20181897T1 (pt)
HU (1) HUE040769T2 (pt)
IL (4) IL236315A (pt)
LT (1) LT2867245T (pt)
MX (3) MX366906B (pt)
MY (3) MY157087A (pt)
NZ (3) NZ743910A (pt)
PE (1) PE20150720A1 (pt)
PH (3) PH12014502871A1 (pt)
PL (1) PL2867245T3 (pt)
PT (1) PT2867245T (pt)
RS (1) RS58005B1 (pt)
SG (2) SG10201703489VA (pt)
SI (1) SI2867245T1 (pt)
TR (1) TR201815811T4 (pt)
TW (2) TWI553120B (pt)
UA (1) UA121959C2 (pt)
WO (1) WO2014005014A2 (pt)
ZA (2) ZA201409397B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2997976A1 (en) 2007-07-27 2016-03-23 Armagen Technologies, Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
KR102318480B1 (ko) 2016-08-25 2021-10-28 제이씨알 파마 가부시키가이샤 항체 융합 단백질의 제조 방법
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7458404B2 (ja) * 2018-12-20 2024-03-29 アーマジェン・インコーポレイテッド イズロン酸－２－スルファターゼ免疫グロブリン融合タンパク質の精製
MX2023004621A (es) * 2020-10-23 2023-06-06 Alexion Pharma Inc Método de control del contenido total de ácido siálico (ctas) durante la fabricación de fosfatasa alcalina.

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
CA2185324A1 (en) 1994-03-16 1995-09-21 Steven D. Rosen Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP1482031B1 (en) 1996-08-30 2015-10-28 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO2000050443A2 (en) 1999-02-26 2000-08-31 Millennium Pharmaceutcals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
IL145893A0 (en) 1999-04-26 2002-07-25 Genentech Inc Cell culture process for glycoproteins
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
JP2003508088A (ja) 1999-09-03 2003-03-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５２個のヒト分泌タンパク質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001238488A1 (en) 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
EP1268541A1 (en) 2000-03-17 2003-01-02 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
JP2003530839A (ja) 2000-04-12 2003-10-21 プリンシピア ファーマスーティカル コーポレイション アルブミン融合タンパク質
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002098455A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
WO2003102132A2 (en) 2002-04-26 2003-12-11 Genetech, Inc. Non-affinity purification of proteins
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
WO2004058800A2 (en) 2002-12-23 2004-07-15 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
CN101444621B (zh) 2003-02-11 2013-11-20 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
ES2385639T3 (es) 2005-06-03 2012-07-27 Ares Trading S.A. Producción de una proteína de unión a IL-18 recombinante
CN101437839A (zh) 2006-03-20 2009-05-20 米德列斯公司 蛋白质纯化
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
EP2245145B1 (en) * 2008-01-18 2016-12-14 BioMarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
PT2485761T (pt) 2009-10-09 2019-05-30 Armagen Inc Métodos e composições para aumentar a atividade da iduronato 2-sulfatase no snc
JPWO2011108451A1 (ja) * 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
EP2585105B1 (en) * 2010-06-25 2017-08-09 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
UA115649C2 (uk) 2010-06-25 2017-12-11 Шае Хюмен Дженетік Терапіс, Інк. Способи та композиції для доставки до цнс ідуронат-2-сульфатази
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
WO2012042857A1 (ja) * 2010-09-28 2012-04-05 共立製薬株式会社 粘膜アジュバント組成物
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR20130114704A (ko) 2011-01-31 2013-10-17 휴렛-팩커드 디벨롭먼트 컴퍼니, 엘.피. 동적으로 튜닝 가능한 산란각을 갖는 산광기
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
CN107596358A (zh) 2018-01-19
JP2015523072A (ja) 2015-08-13
EA202090044A1 (ru) 2020-07-31
CN104583225A (zh) 2015-04-29
US20240043817A1 (en) 2024-02-08
AU2013282395C1 (en) 2016-03-24
TWI587869B (zh) 2017-06-21
PE20150720A1 (es) 2015-05-16
PT2867245T (pt) 2018-11-26
BR112014032567B1 (pt) 2022-09-13
EP2867245B1 (en) 2018-09-12
GT201400303A (es) 2017-08-31
AR091647A1 (es) 2015-02-18
EP2867245A2 (en) 2015-05-06
IL261264B (en) 2021-10-31
JP2016119911A (ja) 2016-07-07
TWI553120B (zh) 2016-10-11
EP2867245A4 (en) 2016-03-09
KR20220002227A (ko) 2022-01-06
US20150313972A1 (en) 2015-11-05
NZ703093A (en) 2017-08-25
HK1249027A1 (zh) 2018-10-26
KR20200143339A (ko) 2020-12-23
PH12015502408B1 (en) 2018-03-26
UA121959C2 (uk) 2020-08-25
AU2018200230B2 (en) 2020-01-02
AU2013282395A1 (en) 2015-01-29
TW201410868A (zh) 2014-03-16
AU2016200469B2 (en) 2017-10-12
PL2867245T3 (pl) 2019-02-28
HK1249026A1 (zh) 2018-10-26
ZA201409397B (en) 2019-10-30
PH12014502871B1 (en) 2015-02-23
SG11201408761VA (en) 2015-01-29
AU2013282395B2 (en) 2015-12-03
CR20140588A (es) 2015-04-06
HK1209767A1 (en) 2016-04-08
JP2018121645A (ja) 2018-08-09
IL236315A0 (en) 2015-02-26
SG10201703489VA (en) 2017-05-30
CN107596357A (zh) 2018-01-19
MX366906B (es) 2019-07-30
PH12014502871A1 (en) 2015-02-23
IL248727A0 (en) 2017-01-31
HRP20181897T1 (hr) 2019-01-11
WO2014005014A3 (en) 2014-02-27
CO7240396A2 (es) 2015-04-17
KR20190064542A (ko) 2019-06-10
IL236315A (en) 2016-11-30
EA034549B1 (ru) 2020-02-19
HK1209431A1 (en) 2016-04-01
TW201703794A (zh) 2017-02-01
CL2014003567A1 (es) 2015-04-24
PH12015502408A1 (en) 2018-03-26
NZ743910A (en) 2019-12-20
DOP2014000294A (es) 2015-03-15
AU2016200469A1 (en) 2016-02-18
IL261264A (en) 2018-10-31
MY180287A (en) 2020-11-27
US9051556B2 (en) 2015-06-09
MX2019008914A (es) 2019-09-26
CA3008945A1 (en) 2014-01-03
US20170073652A1 (en) 2017-03-16
NZ733366A (en) 2019-12-20
ZA201803289B (en) 2021-04-28
US20140004096A1 (en) 2014-01-02
EA201492177A1 (ru) 2015-06-30
DK2867245T3 (en) 2018-11-26
CA2877517A1 (en) 2014-01-03
KR20140004603A (ko) 2014-01-13
CA2877517C (en) 2018-07-31
MY192068A (en) 2022-07-25
WO2014005014A2 (en) 2014-01-03
MX336715B (es) 2016-01-28
JP2020105209A (ja) 2020-07-09
IL287057A (en) 2021-12-01
US9492511B2 (en) 2016-11-15
LT2867245T (lt) 2018-11-12
HUE040769T2 (hu) 2019-03-28
PH12020500027A1 (en) 2021-03-15
EP3441398A1 (en) 2019-02-13
CY1121519T1 (el) 2020-05-29
JP6505629B2 (ja) 2019-04-24
US20190359958A1 (en) 2019-11-28
ES2689468T3 (es) 2018-11-14
TR201815811T4 (tr) 2018-11-21
MY157087A (en) 2016-04-19
RS58005B1 (sr) 2019-02-28
AU2018200230A1 (en) 2018-02-01
JP6171007B2 (ja) 2017-07-26
KR20140002451A (ko) 2014-01-08
US10344270B2 (en) 2019-07-09
US20210317426A1 (en) 2021-10-14
US11530393B2 (en) 2022-12-20
SI2867245T1 (sl) 2018-12-31
MX2015000190A (es) 2015-04-08
KR101380740B1 (ko) 2014-04-11

Similar Documents

Publication Publication Date Title
BR112014032567A2 (pt) purificação de iduronato-2-sulfatase
MX2020003798A (es) Metodos para la purificacion de arilsulfatasa a.
CO6612194A2 (es) Métodos de purificaciñon de adamts 13 y otras proteinas recombinantes y sus composiciones
IN2012DN00801A (pt)
BR112015017307A2 (pt) composições de espécies com baixa acidez e métodos para produção e uso das mesmas
WO2019035880A8 (en) EXOSOMES OF PURIFIED MESENCHYMAL STEM CELLS AND USES THEREOF
BR112018003127A2 (pt) purificação de fkpa e usos do mesmo para produzir polipeptídeos recombinantes
BR112012014937A2 (pt) solução de lavagem e método para cromatografia de afinidade
BRPI0514694B8 (pt) processo de produção de etanercept em cultura de células de produção em larga escala
EA201270713A1 (ru) Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
WO2012031263A3 (en) Cell culture system for bioreactor scale-up of cells
WO2015040497A3 (en) Methods for nuclear reprogramming of cells
BR112015020253A2 (pt) formulações e métodos para produção aumentada de proteína recombinante
BR112015029440A2 (pt) processos para fermentar substrato gasoso contendo co
MX2015005579A (es) Metodo para aislar synagis(r) en ausencia de benzonasa.
TH160179A (th) การทำไอดิลโรเนต-2-ซัลฟาเตสให้บริสุทธิ์
TH160179B (th) การทำไอดิลโรเนต-2-ซัลฟาเตสให้บริสุทธิ์
MX2021016092A (es) Metodos de purificacion de proteinas.
TH75672B (th) การสลายตัวอย่างเลือกจำเพาะของอีเธอร์
RU2012153566A (ru) Способ получения ядерных протеиназ из негистоновых и гистоновых белков растений

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 28/06/2013, OBSERVADAS AS CONDICOES LEGAIS